Colm Farrell

577 total citations
31 papers, 426 citations indexed

About

Colm Farrell is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Colm Farrell has authored 31 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Hematology and 5 papers in Genetics. Recurrent topics in Colm Farrell's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Receptor Mechanisms and Signaling (4 papers) and Platelet Disorders and Treatments (3 papers). Colm Farrell is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Receptor Mechanisms and Signaling (4 papers) and Platelet Disorders and Treatments (3 papers). Colm Farrell collaborates with scholars based in United States, United Kingdom and Switzerland. Colm Farrell's co-authors include S.‐E. SVEHAG, Kathy M. O’Boyle, Alan W. Baird, Henry Søgaard, Edward A. Dominguez, Atul Humar, Kenneth Washburn, Barbara D. Alexander, Emily A. Blumberg and Richard B. Freeman and has published in prestigious journals such as Journal of Neurochemistry, The American Journal of Gastroenterology and European Journal of Pharmacology.

In The Last Decade

Colm Farrell

30 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Colm Farrell United States 11 133 110 65 53 52 31 426
Samuel F. Passi United States 8 93 0.7× 158 1.4× 92 1.4× 49 0.9× 19 0.4× 12 538
J Górski United States 12 142 1.1× 156 1.4× 66 1.0× 23 0.4× 111 2.1× 29 601
Takahide Teramoto Japan 15 53 0.4× 113 1.0× 186 2.9× 21 0.4× 63 1.2× 45 570
Stefania Leoni Italy 12 83 0.6× 120 1.1× 60 0.9× 13 0.2× 72 1.4× 29 498
Michel Goldman Belgium 8 78 0.6× 61 0.6× 165 2.5× 23 0.4× 43 0.8× 16 435
Agustín F. González-Rivero Spain 12 164 1.2× 130 1.2× 72 1.1× 24 0.5× 94 1.8× 77 438
Fumihiko Kaneko Japan 14 102 0.8× 158 1.4× 33 0.5× 26 0.5× 77 1.5× 30 629
D. Gritti Italy 12 119 0.9× 82 0.7× 180 2.8× 25 0.5× 38 0.7× 20 430
Dhriti Mukhopadhyay United States 10 45 0.3× 143 1.3× 148 2.3× 25 0.5× 50 1.0× 11 503

Countries citing papers authored by Colm Farrell

Since Specialization
Citations

This map shows the geographic impact of Colm Farrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colm Farrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colm Farrell more than expected).

Fields of papers citing papers by Colm Farrell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colm Farrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colm Farrell. The network helps show where Colm Farrell may publish in the future.

Co-authorship network of co-authors of Colm Farrell

This figure shows the co-authorship network connecting the top 25 collaborators of Colm Farrell. A scholar is included among the top collaborators of Colm Farrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colm Farrell. Colm Farrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jewell, Roxanne C., Richard J. Mills, Colm Farrell, & Sandra A. G. Visser. (2024). Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies. British Journal of Clinical Pharmacology. 90(10). 2571–2581. 1 indexed citations
2.
Allas, Soraya, Colm Farrell, Sophie Fillon, et al.. (2024). 8406 A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations
3.
Korczowski, Bartosz, et al.. (2023). Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia. Pediatric Research. 94(4). 1547–1554. 5 indexed citations
4.
Yalkinoglu, Özkan, et al.. (2023). Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials. CPT Pharmacometrics & Systems Pharmacology. 12(8). 1157–1169. 4 indexed citations
5.
6.
Song, Ivy, et al.. (2022). Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients with Cytomegalovirus Infections. Transplantation and Cellular Therapy. 28(3). S368–S369. 4 indexed citations
7.
Farrell, Colm, et al.. (2022). Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data. The Journal of Clinical Pharmacology. 63(5). 593–603. 1 indexed citations
8.
Farrell, Colm, et al.. (2021). Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema. Annals of Allergy Asthma & Immunology. 126(6). 707–712. 1 indexed citations
9.
10.
11.
Zhang, Jianping, et al.. (2014). Modeling and Simulation Support Eltrombopag Dosing in Thrombocytopenic Patients with Chronic HCV Infection. Pharmaceutical Research. 32(6). 2015–2028. 6 indexed citations
12.
Farrell, Colm, et al.. (2013). Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. British Journal of Clinical Pharmacology. 77(3). 532–544. 13 indexed citations
13.
Farrell, Colm, et al.. (2013). Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. British Journal of Clinical Pharmacology. 76(6). 897–907. 24 indexed citations
14.
Farrell, Colm, Charles Schweizer, Susan C. Weil, et al.. (2012). Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology. 70(5). 727–734. 15 indexed citations
15.
Zhou, Xiao‐Jian, et al.. (2009). Population Pharmacokinetics of Telbivudine and Determination of Dose Adjustment for Patients With Renal Impairment. The Journal of Clinical Pharmacology. 49(6). 725–734. 3 indexed citations
16.
Dunbar, Joi, et al.. (2007). Population Pharmacokinetics of Extended-Release Injectable Naltrexone (XR-NTX) in Patients With Alcohol Dependence. Journal of Studies on Alcohol and Drugs. 68(6). 862–870. 17 indexed citations
17.
Wiltshire, Hugh, Colm Farrell, Carlos V. Payá, et al.. (2005). Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients. Clinical Pharmacokinetics. 44(5). 495–507. 92 indexed citations
18.
Farrell, Colm, Michael W. Lawlor, A. Dunne, & Kathy M. O’Boyle. (1995). D2 Receptor Antagonists Do Not Modify Guanine Nucleotide‐Sensitive Interactions Between Dopamine and D1 Dopamine Receptors Under In Vitro Conditions. Journal of Neurochemistry. 65(3). 1124–1130. 4 indexed citations
19.
Farrell, Colm, et al.. (1995). Cholinergic activation of Cl− secretion in rat colonic epithelia. European Journal of Pharmacology. 275(1). 83–89. 54 indexed citations
20.
Farrell, Colm & Kathy M. O’Boyle. (1994). The kinetics of [3H]SCH 23390 dissociation from rat striatal dopamine D1 receptors: effect of dopamine. European Journal of Pharmacology Molecular Pharmacology. 268(1). 79–88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel F. Passi Breakdown of academic impact, for papers by J Górski Breakdown of academic impact, for papers by Takahide Teramoto Breakdown of academic impact, for papers by Stefania Leoni Breakdown of academic impact, for papers by Michel Goldman Breakdown of academic impact, for papers by Agustín F. González-Rivero Breakdown of academic impact, for papers by Fumihiko Kaneko Breakdown of academic impact, for papers by D. Gritti Breakdown of academic impact, for papers by Dhriti Mukhopadhyay
Rankless by CCL
2026